709 related articles for article (PubMed ID: 36581880)
1. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
2. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
3. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M; Pal R; Nair K; Mukhopadhyay S
Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
[TBL] [Abstract][Full Text] [Related]
5. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
Kotit S
Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
[TBL] [Abstract][Full Text] [Related]
6. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
7. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M; Docherty KF; Claggett BL; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; McMurray JJV; Solomon SD
Lancet; 2022 Sep; 400(10354):757-767. PubMed ID: 36041474
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
Kroshian G; Joseph J; Kinlay S; Peralta AO; Hoffmeister PS; Singh JP; Yuyun MF
J Cardiovasc Electrophysiol; 2024 Apr; 35(4):715-726. PubMed ID: 38348517
[TBL] [Abstract][Full Text] [Related]
10. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
[TBL] [Abstract][Full Text] [Related]
12. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
[TBL] [Abstract][Full Text] [Related]
13. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
[TBL] [Abstract][Full Text] [Related]
16. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.
Lin Y; Cai Z; Yuan J; Liu H; Pang X; Chen Q; Tang X; Geng Q; Dong S
Cardiovasc Diabetol; 2022 Nov; 21(1):237. PubMed ID: 36348348
[TBL] [Abstract][Full Text] [Related]
17. Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk.
Miller RJH; Nabipoor M; Youngson E; Kotrri G; Fine NM; Howlett JG; Paterson ID; Ezekowitz J; McAlister FA
ESC Heart Fail; 2022 Jun; 9(3):1564-1573. PubMed ID: 35261203
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.
Enzan N; Matsushima S; Kaku H; Tohyama T; Nagata T; Ide T; Tsutsui H
JACC Asia; 2023 Feb; 3(1):93-104. PubMed ID: 36873765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
